REGN · Regeneron Pharmaceuticals, Inc. Healthcare −0.7% on Oct 16
Updated Oct 17 · 9 feeds behind: FDA drug approvals, 1 day, and 8 more · Every feed →
On this page The market view
Price chart Show price chart The interactive REGN chart (by TradingView) loads here.
Behind the stock
Recent disclosures Last 90 days · by disclosure date
Company insiders Insiders 0 buys5 sells
See who traded ↓ Company filings ↓ Is this unusual? ↓
Counts are trades, not people: one person's lots filed on the same day count as one trade. Trades can be disclosed weeks after they happen.
Our take 8 rules fired on REGN
In short: none of these rules has solid or some evidence yet, so they show no clear lean on REGN.
How each did in past tests, against similar stocks over 3 months. Past results don't predict future ones.
⚪ Not enough evidence · +2.0 pp vs similar · 19 signals on REGN
⚪ Not enough evidence · −0.1 pp vs similar · 4 signals on REGN
⚪ Not enough evidence · +4.4 pp vs similar · 3 signals on REGN
All 8 rules ⚪ Not enough evidence · +1.2 pp vs similar · 2 signals on REGN
⚪ Not enough evidence · +2.5 pp vs similar · 2 signals on REGN
⚪ Not enough evidence · +0.4 pp vs similar · 1 signal on REGN
⚪ Not enough evidence · +2.4 pp vs similar · 1 signal on REGN
⚪ Not enough evidence · +4.6 pp vs similar · 1 signal on REGN
🔒 The 0–100 score for REGN, and which of these rules are open on it right now
Members see one number for how strongly these rules agree on REGN, and the day each rule fired. Better-tested rules count more, and so do different kinds of filings that point the same way.
See pricing → Compare with this company’s history
Is disclosure activity unusual? See how many different insiders or members of Congress reported purchases or sales of REGN. Each bar covers 28 days, by disclosure date. Several trades by one person count once in each group and period.
Latest period: Sep 21, 2026–Oct 18, 2026 · UTC dates · today is excluded
Insider purchases 0 filers recorded Short history Insider sales 1 filer recorded Short history Congress purchases 0 filers recorded Within earlier range Congress sales 0 filers recorded Sparse history
Insider purchases
Short history
Only 2 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual.
Latest 28 days 0
Earlier median 0
Earlier range 0–0 Distinct filers per 28 days Scale: 0–1
Oct 20, 2025 Oct 18, 2026
The history behind this view First stored company disclosure: Jul 7, 2026. Newest disclosure across this feed: Oct 16, 2026.
Earlier periods in the comparison: 2. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.
Insider sales
Short history
Only 2 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual.
Latest 28 days 1
Earlier median 2
Earlier range 2–2 Distinct filers per 28 days Scale: 0–2
Oct 20, 2025 Oct 18, 2026
The history behind this view First stored company disclosure: Jul 7, 2026. Newest disclosure across this feed: Oct 16, 2026.
Earlier periods in the comparison: 2. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.
Congress purchases
Within earlier range
This count falls within the range of the 12 earlier comparable periods in this view.
Latest 28 days 0
Earlier median 0
Earlier range 0–1 Distinct filers per 28 days Scale: 0–1
Oct 20, 2025 Oct 18, 2026
The history behind this view First stored company disclosure: Mar 6, 2014. Newest disclosure across this feed: Oct 15, 2026.
Earlier periods in the comparison: 12. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.
Congress sales
Sparse history
Only 1 of 12 earlier periods had activity. That is too little recurring activity to label this count unusual.
Latest 28 days 0
Earlier median 0
Earlier range 0–1 Distinct filers per 28 days Scale: 0–1
Oct 20, 2025 Oct 18, 2026
The history behind this view First stored company disclosure: Mar 6, 2014. Newest disclosure across this feed: Oct 15, 2026.
Earlier periods in the comparison: 12. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.
Exact counts, dates and filings for all four categories Insider purchases · Short history Only 2 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 0; range: 0–0.
Insider purchases: distinct filers in stored disclosures Period and filings Filers History Oct 20, 2025–Nov 16, 2025 — Unavailable Nov 17, 2025–Dec 14, 2025 — Unavailable Dec 15, 2025–Jan 11, 2026 — Unavailable Jan 12, 2026–Feb 8, 2026 — Unavailable Feb 9, 2026–Mar 8, 2026 — Unavailable Mar 9, 2026–Apr 5, 2026 — Unavailable Apr 6, 2026–May 3, 2026 — Unavailable May 4, 2026–May 31, 2026 — Unavailable Jun 1, 2026–Jun 28, 2026 — Unavailable Jun 29, 2026–Jul 26, 2026 0 Partial; excluded Jul 27, 2026–Aug 23, 2026 0 Within stored history Aug 24, 2026–Sep 20, 2026 0 Within stored history Sep 21, 2026–Oct 18, 2026 Latest period 0 Within stored history
Insider sales · Short history Only 2 earlier periods are on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 2; range: 2–2.
Insider sales: distinct filers in stored disclosures Period and filings Filers History Oct 20, 2025–Nov 16, 2025 — Unavailable Nov 17, 2025–Dec 14, 2025 — Unavailable Dec 15, 2025–Jan 11, 2026 — Unavailable Jan 12, 2026–Feb 8, 2026 — Unavailable Feb 9, 2026–Mar 8, 2026 — Unavailable Mar 9, 2026–Apr 5, 2026 — Unavailable Apr 6, 2026–May 3, 2026 — Unavailable May 4, 2026–May 31, 2026 — Unavailable Jun 1, 2026–Jun 28, 2026 — Unavailable Jun 29, 2026–Jul 26, 2026 1 Partial; excluded Jul 27, 2026–Aug 23, 2026 2 Within stored history Aug 24, 2026–Sep 20, 2026 2 Within stored history Sep 21, 2026–Oct 18, 2026 Latest period 1 Within stored history
Congress purchases · Within earlier range This count falls within the range of the 12 earlier comparable periods in this view. Earlier median: 0; range: 0–1.
Congress purchases: distinct filers in stored disclosures Period and filings Filers History Oct 20, 2025–Nov 16, 2025 0 Within stored history Nov 17, 2025–Dec 14, 2025 1 Within stored history Dec 15, 2025–Jan 11, 2026 0 Within stored history Jan 12, 2026–Feb 8, 2026 0 Within stored history Feb 9, 2026–Mar 8, 2026 1 Within stored history Mar 9, 2026–Apr 5, 2026 0 Within stored history Apr 6, 2026–May 3, 2026 0 Within stored history May 4, 2026–May 31, 2026 0 Within stored history Jun 1, 2026–Jun 28, 2026 0 Within stored history Jun 29, 2026–Jul 26, 2026 1 Within stored history Jul 27, 2026–Aug 23, 2026 0 Within stored history Aug 24, 2026–Sep 20, 2026 0 Within stored history Sep 21, 2026–Oct 18, 2026 Latest period 0 Within stored history
Congress sales · Sparse history Only 1 of 12 earlier periods had activity. That is too little recurring activity to label this count unusual. Earlier median: 0; range: 0–1.
Congress sales: distinct filers in stored disclosures Period and filings Filers History Oct 20, 2025–Nov 16, 2025 0 Within stored history Nov 17, 2025–Dec 14, 2025 0 Within stored history Dec 15, 2025–Jan 11, 2026 0 Within stored history Jan 12, 2026–Feb 8, 2026 0 Within stored history Feb 9, 2026–Mar 8, 2026 0 Within stored history Mar 9, 2026–Apr 5, 2026 0 Within stored history Apr 6, 2026–May 3, 2026 0 Within stored history May 4, 2026–May 31, 2026 0 Within stored history Jun 1, 2026–Jun 28, 2026 1 Within stored history Jun 29, 2026–Jul 26, 2026 0 Within stored history Jul 27, 2026–Aug 23, 2026 0 Within stored history Aug 24, 2026–Sep 20, 2026 0 Within stored history Sep 21, 2026–Oct 18, 2026 Latest period 0 Within stored history
How to read this comparison The median is the middle count in up to 12 earlier, non-overlapping 28-day periods; the range runs from the smallest to the largest count. The latest period is excluded from both. A comparison needs at least 6 earlier periods, including 3 with activity. The feed’s latest disclosure must be within 7 days of the current period’s end. This freshness check does not verify complete collection.
Insiders include individuals and reporting entities; only purchase and sale codes enter this view. Congress counts reporting members, including their disclosed family transactions. The same filer can appear in purchases and sales, so these categories should not be added into a net count.
These are stored disclosures, not a complete measure of trading. Reporting delays and collection gaps can change the comparison. More activity does not identify a motive or predict a stock’s return.
Company timeline
What has been happening? May 1, 2026–Oct 16, 2026. Select a month in a category to inspect its records.
Company filings May — Jun 1 Jul 2 Aug — Sep 2 Oct 3
Insiders May — Jun — Jul 2 Aug 4 Sep 6 Oct 28
Public officials May — Jun 1 Jul 1 Aug — Sep — Oct —
FDA & trials May 6 Jun 7 Jul 3 Aug 3 Sep 2 Oct —
Owners & lobbying May 2 Jun — Jul 5 Aug 1 Sep — Oct —
Company filings · Jun 2026 1 on file. This page lists only the newest records.
Company filings · Jul 2026 Record date Jul 30, 2026 1 more on file is not listed here.
Company filings · Sep 2026 Filed Sep 30, 2026 Filed Sep 30, 2026 Company filings · Oct 2026 Filed Oct 6, 2026 Filed Oct 6, 2026 Filed Oct 6, 2026 Insiders · Oct 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Filed Oct 14, 2026 2 more on file are not listed here. See that month’s insider trades →
Public officials · Jul 2026 Disclosed Jul 21, 2026 FDA & trials · May 2026 6 on file. This page lists only the newest records.
FDA & trials · Jun 2026 7 on file. This page lists only the newest records.
FDA & trials · Jul 2026 3 on file. This page lists only the newest records.
FDA & trials · Aug 2026 Record date Aug 31, 2026 Record date Aug 19, 2026 Record date Aug 17, 2026 FDA & trials · Sep 2026 Record date Sep 29, 2026 Record date Sep 1, 2026 Owners & lobbying · May 2026 2 on file. This page lists only the newest records.
Owners & lobbying · Jul 2026 Record date Jul 20, 2026 Record date Jul 20, 2026 Record date Jul 20, 2026 Record date Jul 15, 2026 1 more on file is not listed here.
Owners & lobbying · Aug 2026 Record date Aug 3, 2026 All 47 records in this snapshot Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Disclosed Oct 15, 2026 Filed Oct 14, 2026 Filed Oct 6, 2026 Filed Oct 6, 2026 Filed Oct 6, 2026 Filed Sep 30, 2026 Filed Sep 30, 2026 Record date Sep 29, 2026 Filed Sep 3, 2026 Filed Sep 2, 2026 Filed Sep 2, 2026 Record date Sep 1, 2026 Record date Aug 31, 2026 Record date Aug 19, 2026 Record date Aug 17, 2026 Filed Aug 10, 2026 Record date Aug 3, 2026 Record date Jul 30, 2026 Disclosed Jul 21, 2026 Record date Jul 20, 2026 Record date Jul 20, 2026 Record date Jul 20, 2026 Record date Jul 15, 2026 Month counts include every record on file. The lists show the newest records on this page. A dash means none on file that month. Trades use disclosure dates; contract dates follow the source record. Nearby events do not establish the cause of a price move.
Who's buying and selling · last 90 days Company insiders 0 buys · 5 sells (32 filed lots) · $6.5M sold
▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $361K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $163K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $97.7K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $41.9K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $292K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $39.1K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $26.5K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $12.1K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $173K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $19.1K disclosed Oct 15 · filed 1 day after the trade See every insider trade on REGN → Filings & events Company filings (8-K) 43 Events the company must report to the SEC within days — results, deals, departures, restatements.
What it files 8-Ks about Quarterly or yearly results · item 2.02 17 Shareholder vote results · item 5.07 5 Directors or officers joined, left or got new pay · item 5.02 3 Shared information with investors · item 7.01 2 Signed a major agreement · item 1.01 1 Other events · item 8.01 1 Filing red flags 56 Warning signs in the company's own SEC filings — going-concern doubts, control weaknesses, staff comment letters, late filings, restatements, Wells notices, clinical holds, dividend cuts.
FDA and clinical trials 76 Drug approvals, recalls, clinical-trial updates and FDA advisory meetings.
Lobbying 90 Lobbying reports filed with the Senate for the company.
$11.6M across 90 reports
Issues named in the most reports Aug 3, 2026 Lobbying for Regeneron Pharmaceuticals, Inc. ↗ $50K · by Crane Strategies Jul 20, 2026 Lobbying for Regeneron Pharmaceuticals, Inc ↗ $630K · by Regeneron Pharmaceuticals, Inc Jul 20, 2026 Lobbying for Regeneron Pharmaceuticals, Inc. ↗ $50K · by Arnold & Porter Kaye Scholer LLP Jul 20, 2026 Lobbying for Regeneron Pharmaceuticals, Inc. ↗ $90K · by Bgr Government Affairs Jul 15, 2026 Lobbying for Regeneron Pharmaceuticals Inc. ↗ $90K · by Checkmate Government Relations Planned insider sales (Form 144) 65 Notices insiders file before they sell certain shares, such as ones they got straight from the company.
6 in the last 90 days · 65 notices on file
The notices on file don't give the sale's size; each sale shows up under company insiders once it is reported.
5% owners (13D / 13G) 1 Investors who reported owning 5% or more — 13D for owners who may push for changes, 13G for owners who just hold.
Push for changes, or just hold? Filed by Vanguard Capital Management LLC
Biggest named funds (13F) The largest REGN holdings among the well-known funds whose quarterly 13F filings we read — opens here.
Every disclosed trade on REGN ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $361K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $163K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $97.7K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $41.9K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $292K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $39.1K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $26.5K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $12.1K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $173K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $19.1K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $10.6K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $218K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $4.5K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $20.6K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $29.6K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $354K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $207K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $18.2K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $296K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $214K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $56.3K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $80.7K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $167K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $51.2K disclosed Oct 15 · filed 1 day after the trade ▼ SELL Andrew J Murphy Co-Chief Scientific Officer REGN Regeneron Pharmaceuticals, Inc. $147K disclosed Oct 15 · filed 1 day after the trade See all 61 trades on REGN → People & votes Which members of Congress traded REGN, sponsored bills that touch it and voted on them — opens here.